Flipping the Compliance Model for Life Sciences

By early 2025, the FDA had authorized close to 1,000 AI-enabled medical devices. That number captures how fast life sciences is moving: shorter R&D cycles, software and AI embedded in more products, and new entrants bringing ideas to market faster than before.

This pace can produce more effective treatments for a wider range of patients. But the requirements for demonstrating safety and efficacy are also increasing, while compliance practices have not evolved at the same speed. Many life sciences companies still manage quality and regulatory obligations much as they did twenty years ago. That gap is now a genuine bottleneck for the people developing life-saving products. I find that hard to accept. When a treatment is ready, a compliance process built for a slower era shouldn't be the thing standing between it and a patient.

The enforcement trend is moving in the same direction. FDA warning letters rose from 2.98 to 4.27 per 100 inspections between 2019 and 2023, an increase of 43 percent. Medical device warning letters rose from 24 in FY2023 to 47 in FY2024. Regulatory scrutiny is increasing, and agencies' assessment capabilities will continue to expand as they adopt AI.

What's wrong with the status quo?

For decades, the compliance playbook has remained largely unchanged: develop SOPs, establish internal processes, document activities, and then scramble before an audit to compile everything regulators need to see.

Teams typically respond in four ways: manual tools, traditional systems, general-purpose AI, or more people and consulting support. None addresses the underlying problem.

Some teams rely on spreadsheets, shared drives, and paper-based workflows that require constant human coordination. Others use traditional QMS, PLM, or RIM tools that are reactive by design. Gaps get assessed and patched just before, or after, an audit. Compliance perpetually lags product development.

Some teams are experimenting with general-purpose AI tools such as ChatGPT and Claude. Without validation, integration with business context, or adherence to policy rules, the outputs require close human review. Underneath all of this, the default response is often more headcount and consulting support. Costs rise with growth, and regulatory velocity remains capped by available bandwidth.

All four approaches share the same flaw: enormous effort goes into building and running the systems, while no one can efficiently measure progress against the one thing that actually matters, which is the regulation itself. That, to me, is the real problem worth solving. Everything else is just optimizing the busywork.

Why now?

Medical device companies now operate across the FDA's Quality Management System Regulation, ISO 13485, EU MDR, and MDSAP. Products with software components also face AI- and SaMD-specific requirements, including ISO 42001 and IEC 62304. Managing compliance across these frameworks and markets can slow product development and delay submissions and approvals.

Pharma faces a different source of pressure. Between 2025 and 2030, more than 70 blockbuster drugs, and nearly 200 drugs in total, are expected to lose exclusivity. Estimates put the revenue at risk from this patent cliff above $300 billion. The industry is responding with compressed R&D cycles, acquisitions, and parallel market-entry programs. Companies must now manage a broader regulatory scope under greater time pressure than ever before.

Quality and compliance teams are being asked to do more, faster, under greater complexity than at any point in the last two decades. The old model cannot absorb that pressure.

Flipping the model

There is a better approach, and I'm convinced it's the only model that survives what's coming: flip the sequence entirely.

The regulation-first approach works with or without AI. What agents add is the ability to operate it continuously, at scale, across multiple frameworks.

Instead of building from process to regulation, begin with the regulation itself (FDA, ISO, GxP, etc.) and work backward. Translate unstructured regulatory standards into objective, measurable controls. Mapping those controls to your business data gives a clear, live picture of exactly where you stand. And with agentic capabilities, that visibility never goes stale. Gaps get identified and remediated proactively, before an audit ever surfaces them. Flipping the sequence doesn't mean abandoning the system of record. You still need a rock-solid quality system underneath. What changes is the starting point: the regulation leads, and your system of record now feeds a layer that acts on it, instead of sitting idle until the next audit scramble.

Compliance is a category being rebuilt around AI, and financial services is furthest along. Global banks already use automation to monitor controls and manage risks continuously, transforming work from KYC to transaction monitoring. The same shift is coming to life sciences, where the output is a safe product reaching a patient rather than a filing.

We are applying this model through the Qualio Platform and its agents. They connect regulatory requirements to the company's processes, records, and evidence, then help teams identify gaps and drive remediation. This is how we deliver agentic compliance in practice. It is the product expression of the broader shift described in The Agentic Compliance Era.

The process works as follows:

1. Leaders identify the regulatory frameworks that apply to the organization.
2. Qualio translates those frameworks into objective controls.
3. The platform assesses the company's processes, data, documents, and other evidence against those controls.
4. Agents identify and prioritize gaps, propose remediation, and route work to the right owners.
5. The platform re-checks the evidence as work is completed, keeping the compliance posture current.

This doesn't take humans out of the loop. It changes what they spend their time on. The system initiates the work and carries the load, while the team approves at critical regulated control points and every action is captured in the audit trail. Companies can start with tight oversight where the stakes are highest and widen the agents' boundary as confidence grows.

In practice, this replaces a periodic audit-readiness scramble with a continuously current view of posture, gaps, severity, and ownership. Teams spend less time chasing evidence, identify problems earlier, and make faster progress toward new frameworks and regulatory milestones.

The regulatory bar is only rising, and the companies that keep treating compliance as a manual, after-the-fact scramble will eventually be forced to choose between speed and safety. I don't accept that trade-off. When you flip the model, starting from the regulation, measuring against it continuously, and letting agents carry the load, compliance stops being the brake on life sciences and becomes the engine.

That is the shift we are building at Qualio: the move from compliance as documentation to compliance as a system of action. Every week removed from audit preparation, and every gap caught before a regulator finds it, helps a safe product reach the people who need it sooner. That is the work that matters to us.

[CTA: See how the Qualio Platform works → qualio.com]